Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial.
Author
Hill, Nathan RLasserson, Daniel
Thompson, Ben
Perera-Salazar, Rafael
Wolstenholme, Jane
Bower, Peter
Blakeman, Thomas
Fitzmaurice, David
Little, Paul
Feder, Gene
Qureshi, Nadeem
Taal, Maarten
Townend, Jonathan
Ferro, Charles
McManus, Richard
Hobbs, F D Richard
Publication date
2022-12-12
Metadata
Show full item recordAbstract
None availableCitation
Hill NR, Lasserson D, Thompson B, Perera-Salazar R, Wolstenholme J, Bower P, Blakeman T, Fitzmaurice D, Little P, Feder G, Qureshi N, Taal M, Townend J, Ferro C, McManus R, Hobbs FDR. Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials. 2022 Dec 12;23(1):999. doi: 10.1186/s13063-022-06972-9. Erratum for: Trials. 2014 May 08;15:160.Type
CorrigendumPMID
36510220Journal
TrialsPublisher
BMCae974a485f413a2113503eed53cd6c53
10.1186/s13063-022-06972-9